Phase 2 to Assess Efficacy and Safety in AR882 Alone or in Combination With Allopurinol in Patients With Tophaceous Gout

Study Purpose

This study will assess the serum urate lowering effect, tophi reduction, and safety of AR882 alone and in combination with allopurinol in patients with tophaceous gout at two doses compared to allopurinol over 24 weeks.

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Interventional
Eligible Ages 18 Years - 75 Years
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

  • - History of gout.
  • - at least 1 measurable tophus on the hands/wrists and/or feet/ankles ≥ 5 mm and ≤ 30 mm in the longest diameter.
  • - Patients who are NOT on approved ULT must have sUA > 7 mg/dL.
  • - Patients who are on medically appropriate ULT must have sUA > 6 mg/dL.
  • - Estimated Glomerular Filtration Rate (eGFR) ≥ 45 mL/min/1.73m2.

Exclusion Criteria:

  • - Malignancy within 5 years, except for successfully treated basal or squamous cell carcinoma of the skin.
  • - Pregnant or breastfeeding.
- History of kidney stones

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT05253833
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Phase 2
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

Arthrosi Therapeutics
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

R Keenan, MD
Principal Investigator Affiliation Arthrosi Therapeutics
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Industry
Overall Status Recruiting
Countries New Zealand, United States
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Gout, Arthritis, Gouty, Hyperuricemia, Gout Chronic
Arms & Interventions

Arms

Active Comparator: Group 1

Allopurinol once daily for 24 weeks

Experimental: Group 2

AR882 Dose 1 x 2 weeks, then Dose 2 x 22 weeks

Experimental: Group 3

AR882 Dose 1 + Allopurinol for 24 weeks

Interventions

Drug: - AR882 Dose 1

Solid Oral Capsule

Drug: - AR882 Dose 2

Solid Oral Capsule

Drug: - Allopurinol Tablet

Solid tablet

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

Arthrosi Investigative Site (410), Birmingham, Alabama

Status

Recruiting

Address

Arthrosi Investigative Site (410)

Birmingham, Alabama, 35233

Site Contact

Arthrosi Site

[email protected]

+1 949-393-2676

Arthrosi Investigative Site (403), Phoenix, Arizona

Status

Recruiting

Address

Arthrosi Investigative Site (403)

Phoenix, Arizona, 85032

Site Contact

Arthrosi I Site

[email protected]

+1 949-393-2676

Arthrosi Investigative Site (416), Sun City, Arizona

Status

Recruiting

Address

Arthrosi Investigative Site (416)

Sun City, Arizona, 85351

Site Contact

Arthrosi Site

[email protected]

+1 949-393-2676

Arthrosi Investigative Site (417), Tucson, Arizona

Status

Recruiting

Address

Arthrosi Investigative Site (417)

Tucson, Arizona, 85704

Site Contact

Arthrosi I Site

[email protected]

+1 949-393-2676

Arthrosi Investigative Site (402), Tampa, Florida

Status

Recruiting

Address

Arthrosi Investigative Site (402)

Tampa, Florida, 33606

Site Contact

Arthrosi Site

[email protected]

+1 949-393-2676

Arthrosi Investigative Site (404), Boise, Idaho

Status

Recruiting

Address

Arthrosi Investigative Site (404)

Boise, Idaho, 83713

Site Contact

Arthrosi Site

[email protected]

+1 949-393-2676

Arthrosi Investigative Site (409), Ann Arbor, Michigan

Status

Recruiting

Address

Arthrosi Investigative Site (409)

Ann Arbor, Michigan, 48109

Site Contact

Arthrosi Site

[email protected]

+1 949-393-2676

Arthrosi Investigative Site (406), Greensboro, North Carolina

Status

Recruiting

Address

Arthrosi Investigative Site (406)

Greensboro, North Carolina, 27410

Site Contact

Arthrosi Site

[email protected]

+1 949-393-2676

Arthrosi Investigative Site (408), Myrtle Beach, South Carolina

Status

Recruiting

Address

Arthrosi Investigative Site (408)

Myrtle Beach, South Carolina, 29577

Site Contact

Arthrosi I Site

[email protected]

+1 949-393-2676

Arthrosi Investigative Site (401), Dallas, Texas

Status

Recruiting

Address

Arthrosi Investigative Site (401)

Dallas, Texas, 75231

Site Contact

Arthrosi Site

[email protected]

+1 949-393-2676

International Sites

Arthrosi Investigative Site (201), Auckland, New Zealand

Status

Recruiting

Address

Arthrosi Investigative Site (201)

Auckland, , 1023

Site Contact

Arthrosi Site

[email protected]

+1 949-393-2676